Prudent Man Advisors LLC Sells 111 Shares of Novartis AG (NYSE:NVS)

Prudent Man Advisors LLC lowered its stake in Novartis AG (NYSE:NVSFree Report) by 3.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,130 shares of the company’s stock after selling 111 shares during the period. Prudent Man Advisors LLC’s holdings in Novartis were worth $319,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Moneta Group Investment Advisors LLC increased its stake in shares of Novartis by 102,209.0% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 4,522,057 shares of the company’s stock valued at $410,241,000 after purchasing an additional 4,517,637 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Novartis by 103.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,992,558 shares of the company’s stock worth $174,847,000 after acquiring an additional 1,010,806 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Novartis by 27.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,781,596 shares of the company’s stock worth $244,085,000 after acquiring an additional 594,194 shares during the last quarter. Morgan Stanley boosted its stake in shares of Novartis by 6.2% in the 4th quarter. Morgan Stanley now owns 6,488,196 shares of the company’s stock valued at $588,609,000 after purchasing an additional 377,693 shares in the last quarter. Finally, CI Private Wealth LLC bought a new stake in shares of Novartis during the 4th quarter valued at approximately $23,307,000. Institutional investors and hedge funds own 7.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on NVS. Morgan Stanley began coverage on shares of Novartis in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 target price on the stock. StockNews.com initiated coverage on Novartis in a report on Wednesday, December 6th. They set a “strong-buy” rating on the stock. Finally, HSBC cut Novartis from a “buy” rating to a “hold” rating in a report on Monday, December 18th.

View Our Latest Stock Report on Novartis

Novartis Trading Down 1.4 %

NVS opened at $99.65 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.15 and a quick ratio of 0.93. Novartis AG has a fifty-two week low of $79.98 and a fifty-two week high of $108.78. The company’s 50 day moving average price is $102.77 and its two-hundred day moving average price is $100.27. The firm has a market capitalization of $211.22 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 1.56 and a beta of 0.56.

Novartis (NYSE:NVSGet Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The company had revenue of $11.42 billion for the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a return on equity of 29.90% and a net margin of 29.83%. During the same quarter last year, the business earned $1.51 earnings per share. As a group, research analysts predict that Novartis AG will post 7.19 earnings per share for the current year.

About Novartis

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Articles

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.